Home Blog Page 2893

Unlocking trading flexibility: the power of Octa Broker’s swap-free accounts


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 25 July 2025 – In a dynamic and somewhat dangerous world of currency trading, it is critical to understand every element that impacts your potential profitability. While market spreads and brokers’ commissions form an integral component of trading costs, Forex swap points also play a major role in everyday operations, and yet they are often overlooked and misunderstood by traders. Although sometimes, swap points can be positive and generate a stable income for a trader, most of the time, they represent a recurring cost and can be a serious drag on profitability, especially for traders who prefer to hold positions overnight. This is why Octa, a globally regulated and trusted broker since 2011, provides a significant convenience by offering swap-free accounts for traders.

Octa Broker

Swap points explained
When opening a Forex trade, a trader essentially borrows one currency to buy another. However, each currency has an associated interest rate, set by the respective central bank. The difference between these two interest rates in a Forex pair is what makes a ‘swap point’. In essence, a Forex swap point (also known as a ‘rollover fee’, ‘overnight interest’ or ‘holding cost’) is the interest rate differential between the two currencies. It is applied to positions held open overnight and is credited or debited automatically while being reflected in the final profitability of a trade.

Let’s consider an example with a transaction involving two currencies with significantly different interest rates: the Australian dollar (AUD) and the Japanese yen (JPY). The Reserve Bank of Australia (RBA) has set its policy rate at 3.85%, and the Bank of Japan (BoJ) at 0.5%.

Suppose you want to short (sell) AUDJPY at a 97.00 exchange rate and you initiate a full 1.0 lot position. A short one lot position means you sell 100,000 Australian dollars (AUD) against the Japanese yen (JPY). In order to sell something that you do not own, you need to borrow it first. So, you borrow 100,000 AUD and pay interest (cost). Then, you place the Japanese yen (that you bought) in a bank deposit for one day (overnight) and receive interest (income). If the interest rate on the Australian dollar loan is 3.85%, then you pay 10.55 Australian dollars per day (100,000 x 3.85% / 365). If the interest rate on the yen deposit is 0.5%, you will receive 132.9 yen per day (100,000 x 97 x 0.5% / 365), or just 1.37 Australian dollars at an exchange rate of 97.00. Thus, at the end of the day, the trader will incur a swap loss of 9.18 Australian dollars. And this will be a recurring cost every 24 hours. Not a very comfortable situation to be in, is it?

Furthermore, even if a trader decides to trade currencies with relatively similar rates of interest and buy a higher-yielding currency against a lower-yielding currency, the swap rate may still be negative as brokers often add their markup or discount to the interbank swap rates.

Why the absence of swap points at Octa Broker is so convenient
For many Forex traders, particularly those employing mid-term to long-term strategies, the accumulation of swap points can significantly eat into potential profits or exacerbate losses. This is where Octa Broker’s ‘0% swaps’ policy becomes a game-changer. Indeed, Octa Broker has been trusted by millions of traders around the world precisely for its transparent trading conditions, no hidden tricks, and honest and convenient trading without swap points.

Here are the benefits of having a 0% swap rate:

  • Reduced trading costs

The most obvious benefit is the elimination of recurring overnight fees. For traders who hold positions for days, weeks, or even months, these small daily charges can quickly add up to a substantial amount, impacting overall profitability. By removing swaps, Octa Broker helps traders keep more of their earnings.

  • Flexibility in trading strategies

Traders aiming to capitalise on longer-term market trends no longer have to worry about the mounting cost of holding positions overnight. 0% swap rate frees them and allows them to focus solely on market analysis and price action without the added pressure of daily swap calculations.

  • Simpler profit/loss calculation

Without swap points, calculating your net profit or loss on a trade becomes much more straightforward. You only need to consider the entry price, exit price, and any commissions or spreads, removing a variable that can complicate financial planning and risk management.

  • No unpleasant surprises

Swap rates can fluctuate based on central bank decisions and even market liquidity. Octa Broker’s swap-free offering removes this element of uncertainty, providing a more predictable trading environment.

  • Accessibility for all traders

For new traders, understanding and factoring in swap points can be an additional layer of complexity. Swap-free accounts simplify the learning curve, allowing them to focus on core trading principles. Furthermore, for traders whose religious beliefs prohibit earning or paying interest, swap-free accounts offer an ethical and compliant way to participate in the Forex market.

Octa Broker’s commitment to offering 0% swaps on its trading instruments aligns with a trader-centric approach. This transparency is a cornerstone of how Octa builds trust with clients, empowering them with greater control over their trading costs and fostering more flexible strategy implementation. Ultimately, this contributes to a more transparent and convenient trading experience where traders can trust their broker to prioritise their success. For anyone considering holding forex positions for more than a day, the absence of swap points is a compelling advantage worth serious consideration. Along with other conditions benefiting traders, the zero-swap policy is one of the crucial tools that reliable brokers offer their clients to help them successfully navigate the markets.

___

Disclaimer: This press release does not contain or constitute investment advice or recommendations and does not consider your investment objectives, financial situation, or needs. Any actions taken based on this content are at your sole discretion and risk—Octa does not accept any liability for any resulting losses or consequences.
Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including improving educational infrastructure and funding short-notice relief projects to support local communities.
In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 25, 2025 /PRNewswire/ — On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company”) listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code “09887”.

The clinical-stage biotech company priced its IPO at HKD 35 per share, offering 36.86 million shares (excluding green shoe option). The deal included a Hong Kong public tranche of 16.03 million shares (43% of the total) and an international placement of 20.84 million shares (57%). Morgan Stanley and CITIC Securities acted as joint sponsors of the transaction.

Gross proceeds totaled approximately USD 189 million (including green shoe option). According to Leads Biolabs, the proceeds will be allocated as follows:

  • ~65% for ongoing and planned clinical trials and regulatory affairs;
  • ~15% for advancing preclinical assets, expanding existing pipelines, and optimizing technology platforms
  • ~10% for upgrading manufacturing capacity and commercialization preparedness post-approval;
  • ~10% for working capital and general corporate purposes.

Dr. Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs, commented:

“Our HKEX debut represents a major leap from laboratory innovation to global capital markets, accelerating our innovation-driven international expansion. For more than a decade, we’ve pursued one goal: becoming a global leader in immuno-oncology therapeutics. At this inflection point, we reaffirm our founding commitment to eradicating disease while maintaining the entrepreneurial vigor that defines us. Through strengthened global execution and accelerated translation of breakthrough therapies from bench to bedside, we will deliver paradigm-shifting treatments to patients across the globe.

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune, and other severe diseases both in China and globally. The Company has built a differentiated pipeline of 14 innovative drug candidates, including six clinical-stage drug candidates, of which four lead products are among the top-tier clinically advanced candidates globally.

Leads Biolabs operates an integrated business model encompassing in-house discovery, development and commercialization of innovative tumor immunotherapies. The Company has strategically developed assets in three areas: Immuno-oncology 2.0 (IO 2.0), T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Its oncology pipeline includes 12 investigational products, including 3 monoclonal antibodies, 5 bispecific antibodies, 3 ADCs and 1 bispecific fusion protein. The Company is also progressing two promising candidates for autoimmune diseases—a bispecific fusion protein and a trispecific antibody. 

Leads Biolabs’ R&D is powered by multiple proprietary technology platforms that feature integrated, AI-powered and diversified antibody engineering capabilities, including LeadsBody™ (a CD3 T-cell engager platform), X-body™ (a 4-1BB engager platform) and its linker-payload platform for ADC development. These platforms have demonstrated clinical proof-of-concept, particularly with bispecific antibody combinations.

The LeadsBody™ platform delivers strong technological capabilities for developing CD3-targeted bispecific antibodies. Its innovative molecular design enables precise affinity modulation between TCEs and both CD3 and tumor-associated antigens (TAAs). With spatially optimized steric hindrance architecture, the platform enables conditional T-cell activation exclusively within the tumor microenvironment (TME), significantly lowering the risk of cytokine release syndrome (CRS) and systemic toxicity. This molecular engineering approach is designed to optimize the therapeutic index through customized spatial configurations that reduce treatment interruptions due to toxicity. By minimizing adverse systemic effects, the platform enables extended treatment durations and, ultimately, aims to improve patient quality of life (QoL).

Building on this platform, Leads Biolabs has established a position of leadership in the promising field of solid tumor immunotherapies. The company has developed six differentiated TCE therapeutic candidates, forming a portfolio spanning three major therapeutic areas: hematologic malignancies, solid tumors, and autoimmune diseases.

Hematologic Malignancies:

  • LBL-034: A GPRC5D/CD3 bispecific antibody for the treatment of multiple myeloma (MM)
  • LBL-043: A LILRB4/CD3 bispecific antibody targeting acute myeloid leukemia (AML) and multiple myeloma (MM)

Solid Tumors:

  • LBL-033: A MUC16/CD3 bispecific antibody targeting solid tumors overexpressing MUC16, with a focus on gynecologic cancers including ovarian cancer, cervical cancer, and endometrial carcinoma
  • LBL-054: A CDH17/CD3 T-cell engager under development for colorectal cancer (CRC), gastric cancer, pancreatic ductal adenocarcinoma (PDAC), and neuroendocrine neoplasms (NENs)
  • LBL-058: A first-in-class TCE-ADC (antibody-drug conjugate) targeting DLL3, demonstrating encouraging efficacy in DLL3-positive small cell lung cancer (SCLC) and NENs

Autoimmune Diseases:

  • LBL-051: A first-in- class CD19/BCMA/CD3 trispecific antibody designed to block autoantibody production by B cells and plasma cells while regulating B-cell hyperactivation, differentiation, and plasmacytic transformation. The candidate’s unique mechanism of action enables broad-based B-cell modulation, potentially delivering superior clinical outcomes. The program is being advanced through a strategic collaboration with NewCo, a portfolio company of leading biotech investor Aditum Bio.

The company’s X-body™ platform utilizes advanced antibody engineering to develop 2:2 bispecific antibody structures. Its lead candidate, LBL-024 (PD-L1/4-1BB), represents a key advance in 4-1BB agonist therapies, becoming the first agent in this class to enter global registrational trials. The platform’s 2:2 configuration is designed to restrict 4-1BB activation to the tumor microenvironment (TME), addressing systemic toxicity issues, particularly hepatotoxicity, that have undermined earlier efforts in this category. This platform-driven approach enables precise control of immune activation within the TME, minimizing off-target adverse effects while reactivating exhausted T cells and driving clonal expansion. The mechanism has shown particular promise in tumors resistant to PD-1/PD-L1 inhibitors, as well as in so-called immunologically “cold” tumors. The successful execution of this strategy with LBL-024 underscores its potential as a best-in-class immunotherapy candidate.

At the 2025 ASCO Annual Meeting, Leads Biolabs presented data from a multicenter Phase Ib/II trial evaluating LBL-024 in combination with etoposide and platinum-based chemotherapy in first-line advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC). The study reported a 75.0% objective response rate (ORR) and a 92.3% disease control rate (DCR) among the efficacy-evaluable population (n=52). In the 15 mg/kg cohort, ORR reached 83.3%, with a DCR of 100%. Overall, 57.7% of patients (30/52) achieved tumor reduction exceeding 50%. These results substantially outperformed historical benchmarks for chemotherapy alone, which typically show ORR in the 30–55% range. While progression-free survival (PFS) data were not yet mature at the April 15, 2025 cutoff (median follow-up: 8.2 months), all dose cohorts showed favorable trends compared with historical controls.

EP-NEC is a rare and aggressive cancer with poor advanced-stage outcomes and no approved second-line or later therapies. Recognizing this unmet medical need, China’s National Medical Products Administration (NMPA) granted approval on April 30, 2024 for a pivotal single-arm registrational trial of LBL-024 in EP-NEC, potentially establishing it as the first approved therapy for this indication.

As the world’s first 4-1BB-targeted molecule to have reached registrational stage, LBL-024 could establish 4-1BB as the fourth approved immuno-oncology target following PD-1/L1, CTLA-4 and LAG-3. The candidate has earned Breakthrough Therapy Designation from China’s NMPA for relapsed/refractory EP-NEC and Orphan Drug Designation from U.S. FDA for neuroendocrine neoplasms (NENs).

LBL-024 has also secured regulatory approvals to investigate indications including small cell lung cancer (SCLC), biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and gastric cancer (GC). Early clinical data have shown promising antitumor activity in SCLC, BTC and OC, supporting its potential as a broad-spectrum oncology therapeutic.

Leads Biolabs has enhanced end-to-end capabilities across the entire drug development lifecycle—from early-stage target screening and discovery to preclinical research, clinical development, CMC (Chemistry, Manufacturing, and Controls), and pilot manufacturing. Demonstrating exceptional efficiency, the Company has achieved IND submission within just three years of target selection, significantly outpacing the industry average of 5 to 6 years (based on Frost & Sullivan data). In addition to its proprietary R&D initiatives, Leads Biolabs is exploring strategic collaborations to accelerate clinical development and commercialization of promising drug candidates. The Company is well-positioned to capitalize on market opportunities through out-licensing agreements, co-marketing partnerships, and other strategic alliances. As its clinical-stage assets progress toward commercialization, Leads Biolabs may expand its infrastructure to include commercial-scale manufacturing facilities while bolstering commercialization capabilities—both through collaborative ventures and the development of an in-house sales force.

CLÉ DE PEAU BEAUTÉ WELCOMES NICOLE KIDMAN AS NEW GLOBAL BRAND AMBASSADOR

The critically acclaimed, award-winning Hollywood actor and producer joins the luxury beauty brand, embodying its philosophy of Radiance.

TOKYO, July 25, 2025 /PRNewswire/ — Clé de Peau Beauté, a global luxury skincare and makeup brand, is proud to announce Nicole Kidman as its new Global Brand Ambassador. Renowned for her commanding presence on and off the screen, as well as her passionate advocacy for women’s causes, Kidman perfectly embodies Clé de Peau Beauté’s vision of Radiance—where a blend of intelligence, artistry, and purpose converge. Her appointment marks a significant moment in the brand history.

Introducing Nicole Kidman, Clé de Peau Beauté’s new Global Brand Ambassador
Introducing Nicole Kidman, Clé de Peau Beauté’s new Global Brand Ambassador

Kidman’s acclaimed career reflects the brand’s DNA—intelligent, exquisite, and uncompromising; shaped by conscious choices and an unwavering passion. With each role, she redefines convention, breaking stereotypes with a dedication that has remained consistent throughout her 40-plus-year career. Her elegance and commitment to meaningful change make her an exceptional ambassador, representing a vision of timeless and transformative beauty and radiance.

“We are delighted to welcome Nicole to the Clé de Peau Beauté family,” said Mizuki Hashimoto, Chief Brand Officer of Clé de Peau Beauté. “We believe Radiance is more than appearance; it’s an inner strength that drives positive change. Nicole exemplifies this belief through her inspiring journey, showcasing how passion and purpose unlock a Radiance that empowers others.”

Beyond her artistic achievements, Kidman has made a profound impact as a UN Women Goodwill Ambassador, advocating for women and girl’s empowerment through education, economic opportunities, and the fight against gender-based violence. Her philanthropic work aligns seamlessly with Clé de Peau Beauté’s mission to cultivate beauty that inspires confidence and meaningful change.

“I am thrilled to be joining the Clé de Peau Beauté family,” said Kidman. “I am inspired by the brand’s commitment to celebrate individual beauty across every aspect of a person’s life. I look forward to what we can create together.”

Committed to telling diverse stories, Kidman has showcased a remarkable range of roles, continuously pushing boundaries to amplify underrepresented voices in the film industry. Her bold choices reflect her commitment to infusing artistry with purpose, aligning with the vision of Radiance as a source of empowerment.

A true symbol of Radiance, Kidman exemplifies the idea that true radiance is cultivated through purpose and positive action. Her journey highlights the transformative power of beauty, inspiring others to embrace their own unique beauty and light.

-Ends-

About Clé de Peau Beauté
Clé de Peau Beauté, a luxury brand of Shiseido Co., Ltd., was established in 1982, symbolizing elegance and science. Its name means ‘key to skin’s beauty.’ The brand believes true radiance comes from within, driven by positive intentions and actions. By using advanced technologies and carefully sourced ingredients, Clé de Peau Beauté creates high-end skincare and makeup that enhances the skin’s innate intelligence and radiance. With a focus on exquisite craftsmanship, and science, the brand stands as a leader in luxury skincare and cosmetics.

Available in 26 countries and regions worldwide, Clé de Peau Beauté is dedicated to empowering women and girls through initiatives like the Clé de Peau Beauté Power of Radiance Awards and through its ongoing global partnership with UNICEF.

UNICEF does not endorse any brand, product, or service.

For more information, please visit: www.cledepeau-beaute.com/global/nicolekidman.html

Clé de Peau Beauté Official Instagram: https://www.instagram.com/cledepeaubeaute/

Clé de Peau Beauté Official Tiktok: https://www.tiktok.com/@cledepeaubeaute

Webull Australia Announces Sharesight Integration

  • Webull’s new integration with Sharesight automatically connects trades across global markets, showing real-time tax and performance information for users
  • The integration works with a variety of different account types and trading styles
  • Built with SOC 2 enterprise-level security, sensitive data is kept safe while ensuring seamless functionality

SYDNEY, July 25, 2025 /PRNewswire/ — Webull Securities (Australia) Pty Ltd (‘Webull Australia’), a subsidiary of Webull Corporation (NASDAQ: BULL), the owner of the Webull trading platform, has today announced a partnership with Sharesight, the award-winning online portfolio tracker trusted by over 500,000 investors worldwide.

Webull Australia users can now automatically connect their trades across Australian, U.S., Hong Kong, and Chinese financial markets with Sharesight to see real-time information about key performance metrics, dividend payments, franking credits and tax obligations.

Whether trades are made through a personal account, an SMSF, or a company account, the integration is built to handle the needs of active traders and long-term investors managing sophisticated tax obligations.

To mark the launch, Webull users receive an exclusive 33% discount on a 12-month Sharesight premium subscription, only available through the Webull app.

The new feature uses SOC 2-certified security, ensuring that financial data is handled with the highest standards of privacy and protection.

“This partnership is made for investors who are serious about their portfolio. By working with Sharesight, we’re giving Webull users the clarity and control they need to stay on top of both performance and tax; no spreadsheets needed,” says Rob Talevski, CEO of Webull Securities Australia.

“Through our collaboration with Webull, we believe this a great opportunity to bring our world-class portfolio and tax reporting tools to more Australian investors. This partnership is about making things simple, clear, and helping people invest with confidence,” says Doug Morris, CEO of Sharesight.

Webull’s Sharesight integration will go live on the 25th of July 2025. Investors can learn more by visiting the Webull website or downloading the latest version of the Webull app.

Media contact: 

Cognito for Webull 
Webull@cognitomedia.com  

About Webull Australia

Webull Securities (Australia) Pty. Ltd. is a leading financial services provider, holding an Australian Financial Services Licence (AFSL 536980) and regulated by the Australian Securities and Investments Commission (ASIC). As a trading participant of both the Australian Securities Exchange (ASX) and Cboe Australia, and a principal member of the Stockbrokers and Investment Advisers Association, Webull ensures the highest standards of service and security. All client funds are securely held in client money trust accounts at an approved Authorized Deposit-taking Institution (ADI), and all Australian shares are CHESS-sponsored.

About Webull

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at https://www.webullcorp.com/.

About Sharesight
Sharesight is a powerful portfolio tracking and tax reporting solution trusted by hundreds of thousands of investors worldwide. With automated data imports, performance insights, and tax-ready reporting, Sharesight helps investors and advisors save time and make better decisions. Recognised for its excellence in investment management solutions, including being a finalist in the 2025 Australian Wealth Management Awards in the “Wealth Tech Innovator of the Year” category, Sharesight is utilised by over 500,000 investors across more than 100 countries. The platform offers features such as tracking of over 700,000 global stocks, ETFs, and funds across more than 60 stock exchanges, automated dividend tracking, and detailed tax reporting tools.

USI to Launch Next-Generation 1.6T Optical Module Targeting AI and High-Performance Data Center Applications

SHANGHAI, July 25, 2025 /PRNewswire/ — Universal Scientific Industrial (Shanghai) Co., Ltd. (USI), a global leader in electronic design and manufacturing services, announced its upcoming release of a next-generation 1.6T optical module. This new product is designed to meet the surging demands of high-performance computing (HPC) and AI-driven data centers, enhancing network topology efficiency and addressing the massive data transmission needs driven by ever-expanding AI model sizes.

1.6T Optical Module
1.6T Optical Module

As AI computing power and data volumes continue to grow at an unprecedented pace, traditional electrical transmission can no longer satisfy the requirements for long-distance, high-bandwidth communication. USI’s 1.6T optical module adopts the latest optical communication technologies, doubling the transmission rate of mainstream 800G modules to 1.6 Terabits per second (Tbps). The module is compliant with the IEEE802.3dj_D1.1 standard and seamlessly interoperates with high-speed data center switches, enabling the construction of highly scalable and efficient data center topologies with reduced latency.

USI’s new optical module supports 1310nm single-mode fiber and aligns with the industry-standard DR8 architecture, enabling transmission distances of up to 500 meters. By leveraging single-mode fiber, the solution ensures stability and reliability for high-speed data transfer between server racks. While electrical (e.g., OSFP) and optical (e.g., MPO-16) interfaces follow different standards, USI focuses on core performance and module integration to deliver comprehensive high-efficiency solutions for customers.

In manufacturing, USI has introduced advanced Flip-Chip Bonder equipment to ensure high-precision alignment during the die bonding process, significantly improving yield and module stability. For the optical assembly phase, USI emphasizes fiber alignment as the key to performance. The company will implement automated fiber alignment in mass production to increase production efficiency and units per hour (UPH). Additionally, USI has mastered UV glue parameter optimization for optical assembly and can tailor measurement specifications to meet specific customer requirements, offering highly customized module assembly services.

To strengthen its optical module testing and measurement capabilities, USI’s Intelligent Connectivity Solutions Business Group is planning to establish an in-house testing laboratory. This year, the lab will enable comprehensive optical module validation, accelerating development verification and time-to-market.

“Our R&D team has recognized the growing demand for higher-speed data transmission driven by AI computing workloads,” said Mr. Leo Tai, Associate Vice President of the R&D Center, Intelligent Connectivity Solutions Business Group at USI. “We are proactively investing in 1.6T optical module technology. By building a dedicated test lab, integrating high-precision manufacturing processes, and enhancing optical assembly expertise, USI not only delivers high-performance products but also demonstrates its strength in advanced packaging and high-speed module integration—partnering with customers to build the next generation of AI data centers.”

About USI (SSE: 601231)
USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. With Asteelflash and Hirschmann Car Communication, USI has 30 production and service locations across four continents of Asia, Europe, the Americas, and Africa, and offers customer diversified electronic products with D(MS)2 services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, and material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit www.usiglobal.com and engage with us on LinkedIn and YouTube.

 

LFG!!! Launches AI Alpha Pilot for Meme-Coin Hunters

Institutional‑grade insights, 10–100× leverage, and a $1 million welcome campaign—live today on iOS and Android.

NEW YORK, July 25, 2025 /PRNewswire/ — LFG!!!, incubated by Oraichain Labs, has officially rolled out a trading wallet for meme‑coin hunters on iOS and Android, solving two persistent challenges for retail traders: spotting genuine opportunities amid thousands of risky launches and accessing sophisticated long‑ and short‑trading tools once reserved for institutions. Powered by Thesis.io, AI Pilot on LFG!!! is a non-stop scanner that surfaces fresh “alpha” (promising tokens) on Solana, Sonic and BNB Chain.

Download LFG!!! Now
Download LFG!!! Now

AI Pilot: The Agentic Advantage

At the heart of LFG!!! lies its “AI Pilot” feature, an autonomous system that continuously monitors vast networks of on-chain and off-chain data across Solana, Sonic, and BNB Chain. AI Pilot scans thousands of token launches daily, operates in real-time, tracking smart contract deployments, monitoring whale movements, analyzing social sentiment, and identifying emerging narratives before they reach mainstream attention.

Early users have seen results: internal testing showed a 58.9% win rate on meme trades when guided by Alpha Pilot signals, with many top-performing tokens yielding 50%+ returns in just a few days. Full report: https://link.thesis.io/memereport.

Fast and Flexible Trading, Built In

LFG!!! lets users act on opportunities fast, with a simple and secure trading experience:

  • Prediction markets with 10 to 100x leverage: Use a slider to boost returns and control risk. Trades are settled automatically on-chain.
  • Easy fiat on-ramp: Fund your wallet in minutes via Apple Pay, cards, or PayPal.
  • Self-custodial wallet: You hold the keys and stay in full control of your assets.
  • Multi-chain access: Trade across Solana, Sonic, and BNB Chain with a single wallet.

Launch Promotions

To celebrate the debut, LFG!!! is dropping a $1 million welcome bonus in USDAI, giving $10 to each of the first 100,000 users. There’s also a 50 % fee-share referral reward and a $1,000 X (Twitter) campaign for early community builders. All bonuses are claimable directly in-app.

Download LFG!!! on iOS or Android today: https://lfg.app.link/MRArK06OcVb

About LFG!!!

LFG!!! is incubated by Oraichain Labs, an AI Layer 1 blockchain that powers decentralized applications with trusted data oracles and advanced AI services. The project also integrates Thesis.io to tap into agentic research capabilities and enable deep analysis across massive datasets and real-time AI reasoning.

Together, these foundations support the core vision behind LFG!!!: Let’s Find Gems.

Siemens, PTC, and Dassault Systèmes Named Leaders in ABI Research’s PLM Assessment for Large Discrete Manufacturers; Aras Gaining Momentum

NEW YORK, July 25, 2025 /PRNewswire/ — The Product Lifecycle Management (PLM) market has witnessed significant developments over the past year with the rise of Software-as-a-Service (SaaS), digital twins, and Generative AI (Gen AI) becoming integral for large discrete manufacturers. ABI Research, a global technology intelligence firm, evaluated 10 PLM vendors and accompanying software to determine which solutions are sufficiently servicing the needs of large discrete manufacturers based on levels of innovation and implementation.

2024 Logo

Although distinct in nature, large discrete manufacturers across eight industry verticals (A&D, Automotive, Electronics, Heavy Equipment, Industrial Machinery, Medical Devices, and Other Transportation) share commonalities that are dictating the market. “Large discrete manufacturers are favoring solutions that can be deployed as SaaS, have flexible payment structures, integrated Gen AI copilots, and do not require extensive modification and customization from system integrators or third-party value-added resellers (VARs),” states James Iversen, Industry Analyst.

Siemens, PTC, and Dassault Systèmes are the leading PLM vendors with their respective solutions, Teamcenter, Windchill, and Enovia. Siemens Teamcenter is the overall leader with standout scores coming from incorporating the largest partner ecosystem for external software integration, the highest market share for large discrete manufacturers, and an industry-leading Gen AI position with Teamcenter Copilot. PTC placed second with strengths in digital thread creation, product tracking through real-time updates, and a desirable customer support model for post-sale maintenance. Dassault Systèmes rounds out the leadership category, outperforming the market average by providing robust Model-Based Systems Engineering (MBSE) capabilities, modular and role-based purchasing, along with high scores for digital thread creation with the connection to the 3DEXPERIENCE platform.

Aras and their PLM software Innovator is an Innovation leader, with capabilities rivaling and surpassing those of Siemens, PTC, and Dassault Systèmes. Aras’ highest scores came from strengths in low-code API management, the integration of AI assisting chatbots, and robust Out-of-the-Box (OOTB) functionality so manufacturers are less reliant on SIs and VARs.

Large discrete manufacturers share priorities when it comes to the functionality and deployment of PLM solutions. All require fast time-to-value, flexible solution architecture, and new technology additions such as Gen AI. With the Product Lifecycle Management (PLM) for Large Discrete Manufacturers competitive assessment, vendors and end users can see how PLM software competes in the market, and where vendors can improve offerings to better facilitate the needs of large discrete manufacturers.

These findings are from ABI Research’s Product Lifecycle Management (PLM) For Large Discrete Manufacturers competitive assessment. This report is part of the company’s Industrial and Manufacturing research service, which includes research, data, and ABI Insights.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info

Global
Jason Scheer
Tel: +1.516.624.2558
pr@abiresearch.com

 

Databricks Accelerates Bay Area Growth with New Office in Sunnyvale

New office provides 305,000 square feet for employees, customers and partners to accelerate adoption of the Databricks Data Intelligence Platform

SAN FRANCISCO, July 25, 2025 /PRNewswire/ — Databricks, the Data and AI company, today continues its rapid growth in the San Francisco Bay Area with the expansion into a new 305,000 square foot office in downtown Sunnyvale. This state-of-the-art office is designed to support the company’s accelerated hiring efforts in light of its South Bay R&D team doubling over the past two years, with projections to double again over the next two years, even as the company aggressively leverages its own platform and AI to deliver new products faster. This rapid growth is fueled by increasing enterprise demand for the Databricks Data Intelligence Platform, underscoring the company’s pivotal role in powering data and AI innovation.

Located at 200 West Washington, this strategic location in Sunnyvale allows Databricks to deepen partnerships with its many South Bay customers, including Adobe, Barracuda Networks, Cisco, Intuit, McAfee, Netgear and NVIDIA, while also positioning the company to reach new customers. This new space will be essential for fostering stronger collaboration and empowering Databricks’ product and engineering teams to deliver innovative AI solutions for the region’s leading enterprises.

This news builds on recent Databricks Bay Area momentum. In March, the company announced a new headquarters at One Sansome Street, committed $1 billion to its San Francisco operations over the next three years, and confirmed a five-year extension of its Data + AI Summit in San Francisco, underscoring Databricks’ enduring dedication to the broader Bay Area as the world’s AI capital.

“Silicon Valley has always been at the heart of technological innovation, and this expansion in Sunnyvale marks an exciting new chapter for Databricks,” said Reynold Xin, Co-founder and Chief Architect at Databricks. “This investment will accelerate our pace of research and product development, deepen our collaboration with customers, and help us attract the best minds to push the boundaries of what’s possible with data and AI.”

“Our expansion into Sunnyvale is about more than adding office space — it’s a strategic investment in the exceptional talent driving the future of AI,” said Amy Reichanadter, Chief People Officer at Databricks. “At Databricks, people come to do meaningful, high-impact work, and this expansion is a further investment in fostering the culture of innovation and collaboration that sets us apart.”

Databricks will move into its new Sunnyvale office in late 2026. The company’s expanded presence in Sunnyvale will open up a variety of roles across all functions. For more information about career opportunities at Databricks, please visit the Databricks Careers page.

About Databricks
Databricks is the Data and AI company. More than 15,000 organizations worldwide — including Block, Comcast, Condé Nast, Rivian, Shell and over 60% of the Fortune 500 — rely on the Databricks Data Intelligence Platform to take control of their data and put it to work with AI. Databricks is headquartered in San Francisco, with offices around the globe and was founded by the original creators of Lakehouse, Apache Spark™, Delta Lake, MLflow, and Unity Catalog. To learn more, follow Databricks on X, LinkedIn and Facebook.

Contact: Press@databricks.com